NCT06731504View on ClinicalTrials.gov

HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

July 31, 2028

Conditions
Hematologic Malignancy
Interventions
DRUG

Abatacept

Abatacept is a monoclonal antibody that suppresses T-cell activation through costimulatory blockade. In 2021, abatacept was FDA approved to prevent acute GVHD following allogeneic HCT.

Trial Locations (1)

27705

RECRUITING

Duke University Health System, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
lead

Duke University

OTHER